Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI™ Platform Contract | Launch of B cell Llama™ Nanobody Discovery Platform
Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; MindWalk holds first right to commercialize...
The Company to host an earnings conference call via webcast
MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an application of its proprietary HYFT ®...
MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic...
Validated Across Influenza A and Influenza B, Including H3N2 Subclade K and Zoonotic Influenza A Subtypes H5, H7, H9
Validated Across Influenza A and Influenza B, Including H3N2 Subclade K and Zoonotic Influenza A Subtypes H5, H7, H9
MindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab operations for biologics discovery and development, today announced...
The Company to host an earnings conference call via webcast
MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate...